Analysis of The Cancer Genome Atlas (TCGA) datasets revealed that FSTL3 was associated with poor survival outcomes in multiple cancers, including ovarian, colorectal, pancreatic and lung cancers (Fig. 1A); in comparison, FST had a weaker correlation of poor prognosis for ovarian cancer (Fig. 1B). Here, FST is linked to ovarian carcinoma.